Core Insights - Arvinas is transitioning into a Phase 1 company with 4 programs currently in Phase 1 clinical trials as of early 2026 [2][3] - The company has developed a LRRK2 degrader for neurodegenerative disorders and a KRAS G12D degrader for solid tumors [2] - A BCL6 degrader for hematology is also in development, along with a new clinical trial for a program targeting AR, specifically for Kennedy's disease [3] - The previously leading program, Vepdegestrant, has shown positive pivotal data and an NDA has been filed with the FDA, with a PDUFA date set for early June [4]